Interius BioTherapeutics
Business Services · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Avenue Building 3401 Grays Fry 200 Ste 3...Phone Number
(215) 608-9333Website
www.interiusbio.comRevenue
$11 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Interius BioTherapeutics
Founded in 2021, Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania. It's a gene therapy company based in Philadelphia, PA.Explore more
Interius BioTherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Interius BioTherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Interius BioTherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Interius BioTherapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Interius BioTherapeutics has new funding data
Product Launch: Get notified when Interius BioTherapeutics launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Interius BioTherapeutics
Earning: See what the market has to say on Interius BioTherapeutics recently announced quarterly report
Check if Interius BioTherapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Interius BioTherapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Interius BioTherapeutics
Compare insights from companies similar to Interius BioTherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Interius BioTherapeutics
$11M
51-200
Private
$76M
2021
DM
Dora MitchellSenior VP, Operations & Chief of Staff
Company Profile Activity
Activity Insights
Interius BioTherapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Interius BioTherapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Interius BioTherapeutics.
Interius BioTherapeutics financials insights
Gather financial insights about Interius BioTherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$76M
Interius BioTherapeutics Tech Stack
A closer look at the technologies used by Interius BioTherapeutics
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Person-Based
Project
Research & Development, Compliance, Medical Research, Pharmaceuticals, Regulations
Event
Person-Based
Events, Search, Medical Research
Interius BioTherapeutics News & Media
Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe
German regulatory agency, the Paul Ehrlich Institute, granted approval to expand the INVISE Phase 1 clinical trial evaluating INT2104 for the treatment of B-cell malignancies to EuropeInterius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cellsInterius BioTherapeutics nabs $76m Series A | Venture Capital Journal
Interius BioTherapeutics, a preclinical stage gene therapy company, has raised $76 million in Series A financing.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Interius BioTherapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2021, Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania. It's a gene therapy company based in Philadelphia, PA.... Read More
